Tempest Therapeutics, Inc.

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Investors’ reaction to the success of Tempest Therapeutics, Inc. ’s liver cancer trial hit on 11 October was extraordinary – and a new analysis by Scrip shows just how extraordinary it was. The med

Addition of the PPAR⍺ antagonist TPST-1120 to standard of care in hepatocellular carcinoma (HCC) boosted survival in an ongoing Phase I/IIb study, Tempest Therapeutics, Inc. said on 11 October. The

Scrip asked 30 industry leaders to share their thoughts around what the biopharma industry will do – and what it needs to do – to advance diversity, equity and inclusion (DEI) this year. Their respon